ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential

ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential

Bladder cancer (BCa) is one of the most common malignant tumors that cause death. Approximately 75%–85% of BCa develop into non-muscle-invasive bladder cancer (NMIBC). Bacillus Calmette-Guérin (BCG) is the gold standard for avoiding cystectomy in the treatment of NMIBC. Unfortunately, up to 30% of p...

Full description

Bibliographic Details
Main Authors: Wujun Chen, Ning Liu, Yang Yuan, Meng Zhu, Xiaokun Hu, Wenchao Hu, Shuai Wang, Chao Wang, Binghuan Huang, Dongming Xing
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
NMIBC
ALT-803
pembrolizumab
oportuzumab monatox
BCG
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1040669/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1040669/full

Similar Items